Overview

Phase II Study to Evaluate Safety and Efficacy of Cetuximab in Combination With XELOX for 12 Weeks Followed by Maintenance Treatment With Cetuximab Plus Capecitabine as First-line Treatment in Elderly Patients With Metastatic Colorectal Cancer.

Status:
Terminated

Trial end date:
2009-04-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine confirmed objective response rate to combination therapy with cetuximab plus XELOX for 4 cycles followed by maintenance treatment with cetuximab plus capecitabine as first line treatment in elderly patients with metastatic colorectal cancer

Phase:

Phase 2

Details

Lead Sponsor:

Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Capecitabine
Cetuximab
Oxaliplatin